EAU 2022 Archives - Medical Conferences

Home > Urology > EAU 2022

Read the full Report (pdf)

European Association of Urology
01–04 July 2022
Amsterdam, the Netherlands

Darolutamide performs well across subgroups in mHSPC

Presented By

Prof. Bertrand Tombal, Université Catholique de Louvain, Belgium

Trial

Phase 3, ARASENS

Conference

EAU 2022

Type

News article

22 July 2022 12:33

Online First

Genitourinary Cancer

Does systematic biopsy add value to the detection rate of prostate cancer?

Presented By

Dr Enrico Checcucci, University of Turin, Italy

Conference

EAU 2022

Type

News article

22 July 2022 12:42

PSMA PET/CT cannot replace mpMRI for diagnosis of prostate cancer

Presented By

Prof. Lih-Ming Wong, University of Melbourne, Australia

Trial

Phase 3

Conference

EAU 2022

Type

News article

22 July 2022 12:41

Prostate cancer treatments reduce quality of life

Presented By

Mr André Deschamps, Europa Uomo, Belgium

Trial

EUPROMS 2.0

Conference

EAU 2022

Type

News article

22 July 2022 12:39

PROpel: Good results for abiraterone plus olaparib in mCRPC

Presented By

Prof. Noel Clarke, University of Manchester, UK

Trial

Phase 3, PROpel

Conference

EAU 2022

Type

News article

22 July 2022 12:37

Neoadjuvant hormonal therapy promising in high-risk prostate cancer

Presented By

Prof. Steven Joniau, UZ Leuven, Belgium

Trial

Phase 2, ARNEO

Conference

EAU 2022

Type

News article

22 July 2022 12:35

Darolutamide performs well across subgroups in mHSPC

Presented By

Prof. Bertrand Tombal, Université Catholique de Louvain, Belgium

Trial

Phase 3, ARASENS

Conference

EAU 2022

Type

News article

22 July 2022 12:33

Shorter hospital stay with robotic surgery versus open surgery in bladder cancer

Presented By

Prof. James Catto, University of Sheffield, UK

Trial

Phase 3, iROC

Conference

EAU 2022

Type

News article

22 July 2022 12:30

Improved risk stratification for high-risk NMIBC

Presented By

Mr Florus de Jong, Erasmus University Medical Center, the Netherlands

Conference

EAU 2022

Type

News article

22 July 2022 12:28

Adjuvant atezolizumab may benefit ctDNA-positive patients with post-op muscle-invasive urothelial carcinoma

Presented By

Prof. Jürgen Gschwend, Technical University Munich, Germany

Trial

Phase 3, IMvigor010

Conference

EAU 2022

Type

News article

22 July 2022 12:26

New prognostication in N3 penile cancer

Presented By

Dr James Churchill, St George Hospital, Australia

Conference

EAU 2022

Type

News article

22 July 2022 12:24

KEYNOTE-564: Updated results of adjuvant pembrolizumab in RCC

Presented By

Prof. Thomas Powles, Barts Cancer Institute, UK

Trial

Phase 3, KEYNOTE-564

Conference

EAU 2022

Type

News article

22 July 2022 12:22

Fewer complications with robotic surgery in renal cancer

Presented By

Prof. Marc-Oliver Grimm, Universitätsklinikum Jena, Germany

Trial

Phase 3, OpeRa

Conference

EAU 2022

Type

News article

22 July 2022 12:19

Functional Urology

Novel therapeutic targets for benign prostatic hyperplasia

Presented By

Prof. Richard Bryant, University of Oxford, UK

Conference

EAU 2022

Type

News article

22 July 2022 12:17

Mini-slings non-inferior to standard mid-urethral slings in SUI

Presented By

Prof. Mohamed Abdel-fattah, University of Aberdeen, UK

Trial

SIMS

Conference

EAU 2022

Type

News article

22 July 2022 12:14

Non-inferiority of methenamine hippurate to antibiotics in recurrent UTIs

Presented By

Prof. Christopher Harding, Newcastle University, UK

Trial

ALTAR

Conference

EAU 2022

Type

News article

22 July 2022 12:02

Medical Conferences

EAU 2022

Featured articles

Darolutamide performs well across subgroups in mHSPC

CONTENTS

Online First

Genitourinary Cancer

Does systematic biopsy add value to the detection rate of prostate cancer?

PSMA PET/CT cannot replace mpMRI for diagnosis of prostate cancer

Prostate cancer treatments reduce quality of life

PROpel: Good results for abiraterone plus olaparib in mCRPC

Neoadjuvant hormonal therapy promising in high-risk prostate cancer

Darolutamide performs well across subgroups in mHSPC

Shorter hospital stay with robotic surgery versus open surgery in bladder cancer

Improved risk stratification for high-risk NMIBC

Adjuvant atezolizumab may benefit ctDNA-positive patients with post-op muscle-invasive urothelial carcinoma

New prognostication in N3 penile cancer

KEYNOTE-564: Updated results of adjuvant pembrolizumab in RCC

Fewer complications with robotic surgery in renal cancer

Functional Urology

Novel therapeutic targets for benign prostatic hyperplasia

Mini-slings non-inferior to standard mid-urethral slings in SUI

Non-inferiority of methenamine hippurate to antibiotics in recurrent UTIs